Icosapent ethyl fails to benefit non-hospitalized adults with COVID-19, finds clinical trial

Published On 2021-11-18 03:45 GMT   |   Update On 2021-11-18 03:50 GMT

DALLAS:The purified omega-3 fatty acid, icosapent ethyl, did not result in a statistically significant reduction in hospitalization or death from COVID-19, finds a new late-breaking clinical trial.

A high dose of a purified omega-3 fatty acid, icosapent ethyl was well tolerated; however, it did not substantially reduce incidents of hospitalizations and/or deaths among people with COVID-19.

The clinical trial was presented today at the American Heart Association's Scientific Sessions 2021. 

Researchers sought to determine whether a high dose of pure eicosapentaenoic acid (EPA) ethyl ester, called icosapent ethyl (IPE), would reduce the rate of hospitalizations and/or death among people with COVID-19.

The Prevention and Treatment of COVID-19 With EPA in Subjects at Risk - Intervention Trial (PREPARE-IT 2) included approximately 2,000 men and women, ages 40 and older, who tested positive for COVID-19 and experienced symptoms of the infection (fever, cough, sore throat, shortness of breath or muscle aches) for 7 days or less prior to study enrollment but did not clearly require hospitalization. Participants were randomized to receive either IPE or placebo pills. Those in the treatment arm received 8 grams of IPE as 4 capsules every 12 hours with food for 3 days, followed by 4 grams of IPE as 2 capsules every 12 hours with food for days 4-28. Neither the patients nor their health care professional knew if they received IPE or the placebo.

A subgroup of patients was asked to self-report the severity of their symptoms using a validated symptom diary, the FLU-PRO assessment, at the start of the study and at 28 days.

The researchers found that IPE treatment was safe and well tolerated, though there was a slightly higher rate of participants who stopped taking the pills in the IPE group. There was a positive, though not statistically significant, trend for a benefit with the treatment.

Advertisement

Prescription IPE has been approved by the FDA as an adjunctive therapy to reduce risk of cardiovascular events in some patients. PREPARE-IT 2 used twice the FDA-approved dose of IPE as a "loading dose" the first three days of treatment to examine the safety and tolerability of the higher dose of IPE. A loading dose is a higher amount of medicine given initially, before switching to a lower maintenance dose for the duration of treatment.

"Based on observable outcomes, loading doses of IPE were safe and well tolerated," said study author Rafael Díaz, M.D., director of Estudios Clínicos Latinoamérica in Rosario, Argentina. "It's unclear if a larger trial might support or refute the positive trends noted here with high-dose IPE treatment."

Tags:    
Advertisement
Article Source : American Heart Association Scientific Sessions 2021

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News